Synchron Secures $200M to Advance Stentrode Platform Commercialisation
Synchron has raised $200 million in a Series D funding round to accelerate the commercial rollout of its Stentrode brain-computer interface (BCI) platform and develop next-generation interfaces.
Funding Round and Investors
The investment was led by Double Point Ventures, with participation from ARCH Ventures, Bezos Expeditions, Khosla Ventures, METIS, and NTI. New stakeholders joining include the Australian National Reconstruction Fund (NRF), Qatar Investment Authority (QIA), T.Rx Capital, K5 Global, IQT, and Protocol Labs.
Company Plans and CEO Statement
Synchron plans to use the funds to speed up key clinical trials and expand its multidisciplinary team.
Synchron founder and CEO Tom Oxley said: “We’ve built the first non-surgical brain-computer interface designed for everyday life for people with paralysis. This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field – a next-generation, transcatheter high-channel whole-brain interface.”
By combining innovative funding and clinical focus, Synchron aims to revolutionize BCI technology for practical, everyday use.
Would you like the summary to be more technical or general?